We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

CTLA-4

CTLA-4 antibodies and inhibitors target cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). CTLA-4 is an inhibitory T-cell receptor, a homolog of the costimulatory receptor cluster of differentiation 28 (CD28) that binds the same ligands, B7-1 (CD80) and B7-2 (CD86), on antigen-presenting cells. It binds them with higher affinity than CD28 and so limits costimulation and T-cell activation. Mice lacking CTLA-4 develop massive lymphoproliferation and fatal multiorgan tissue destruction. Most products here are antibodies, such as the anti-CTLA-4 antibodies quavonlimab and gotistobart. Vudalimab is a bispecific antibody against CTLA-4 and programmed cell death protein 1 (PD-1). Davoceticept is listed as a dual inhibitor of CTLA-4 and programmed death-ligand 1 (PD-L1), and AN02 as a CTLA-4 degrader.

1 Item

  • KD6001
    Cat. No.
    A64572
    CAS No.
    2983061-18-1

    KD6001

    KD6001 is a humanized IgG1κ monoclonal antibody that targets CTLA-4, effectively disrupting the interactions between CTLA-4 and its ligands CD80 and CD86, with an IC50 of 16 ng/mL. This antibody promotes the activation of T cells by enhancing the expression of IL-2 and IFNγ in PHA-activated human lymphocytes. KD6001 demonstrates significant antitumor activity, inhibiting tumor growth in various mouse models, including MC38, B16, and Hepa1-6. It is relevant for research applications in cancer, particularly in advanced melanoma, hepatocellular carcinoma, and liver cancer.

    View Details

    Out of stock

    All 3 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...